Allergy & Immunology
RCT: third dose of Moderna mRNA vaccine increases immunity in transplant recipients.
12 Aug, 2021 | 09:56h | UTCEditorial: Third Time’s a Charm — Covid-19 Vaccine Hope for Solid-Organ Transplant Recipients
Related:
[Preprint] 3rd AstraZeneca shot gives strong immunity.
Commentaries on Twitter
..1st randomized trial results of 3rd doses of Moderna vax for 120 people with organ transplants: month 4, their minimum anti-RBD antibody levels were 55% for 3rd dose vs 18% (still increasing a little in the placebo group). No cases of acute rejection https://t.co/BcfeyUEhx5 #IC
— Hilda Bastian, PhD (@hildabast) August 11, 2021
The authors conclude that a third-dose booster of mRNA-1273 vaccine should be considered for transplant recipients. https://t.co/Q3gakSaNjd pic.twitter.com/CMN8f7cq29
— NEJM (@NEJM) August 11, 2021
RCT: Evaluation of Moderna mRNA vaccine in adolescents.
12 Aug, 2021 | 09:58h | UTCEvaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents – New England Journal of Medicine
Related:
Commentaries on Twitter
The mRNA-1273 vaccine was effective in preventing #COVID19 in 12-to-17-year-olds. Immune response was similar to young adults. https://t.co/aC3Dmjqe2T pic.twitter.com/9RxgHApW29
— NEJM (@NEJM) August 11, 2021
The @moderna_tx covid vaccine trial in 3,732 teens, placebo-controlled, published today @NEJM with both excellent safety profile and efficacy vs covid, and immune response as least as good as young adults https://t.co/PVmhjwgwsU pic.twitter.com/3uCmteaWNx
— Eric Topol (@EricTopol) August 11, 2021
Clinical features of vaccine-induced immune thrombocytopenia and thrombosis.
12 Aug, 2021 | 09:05h | UTCCommentary: Largest Study of VITT After COVID-19 Vaccination Digs Into Lab, Clinical Features – TCTMD
Related:
NICE COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis.
Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know.
Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (several articles and resources on the subject)
Commentary on Twitter
The phenotypes of VITT were defined in 220 patients presenting a 14-day median after the first ChAdOx1 nCoV-19 dose. Mortality was 22%. https://t.co/ir0yG5X0BP #COVID19 #IDTwitter pic.twitter.com/iAfxs0I1Ce
— NEJM (@NEJM) August 11, 2021
Guideline: Diagnosis and management of cutaneous lupus erythematosus – Therapy, risk factors and other special topics.
12 Aug, 2021 | 08:55h | UTC
Brief review: Immunobullous disease.
12 Aug, 2021 | 08:37h | UTCImmunobullous disease – Clinical Medicine Journal
Brief review: Advances in atopic dermatitis.
12 Aug, 2021 | 08:32h | UTCAdvances in atopic dermatitis – Clinical Medicine Journal
PRINCIPLE RCT: Inhaled budesonide improves time to recovery from COVID-19 in people at high risk of complications in the community.
11 Aug, 2021 | 08:52h | UTCInvited Commentary: The use of inhaled corticosteroids in early-stage COVID-19
M-A: More than 50 long-term effects of COVID-19.
11 Aug, 2021 | 08:47h | UTCRelated:
Cohort study: Risk factors for long covid in previously hospitalized children.
Viewpoint: The road to addressing Long Covid.
Review: Long covid—mechanisms, risk factors, and management.
Review: Symptoms, complications and management of long COVID.
Studies elucidate poorly understood long COVID.
Long Covid: Half of young adults with COVID-19 have persistent symptoms 6 months after, study finds.
[Preprint] Long Covid: Third of people infected have long term symptoms.
Almost 25% of COVID-19 patients develop long-lasting symptoms, according to a new report.
Perspective | The four most urgent questions about long COVID.
Systematic review: Frequency, signs and symptoms, and criteria adopted for long COVID-19.
Report: 376,000 people in UK have had long Covid symptoms for at least a year.
One third of patients hospitalized with COVID-19 have lung changes after a year
Perspective | They Tested Negative for Covid. Still, They Have Long Covid Symptoms.
Cohort study: One in ten have long-term effects 8 months following mild COVID-19
Long Covid Implications for the workplace
Long Covid in the UK – More than a million affected in February, survey suggests
Covid-19: Middle aged women face greater risk of debilitating long term symptoms
Persistent neurologic symptoms and cognitive dysfunction in non‐hospitalized Covid‐19 “long haulers”
Review | Post-acute COVID-19 syndrome
Long Covid | Four-month clinical status of a cohort of patients after hospitalization for COVID-19
Perspective | Long Covid isn’t as unique as we thought
Attributes and predictors of long COVID
WHO Report: Preparing for Long COVID 2021
Long Covid: Sequelae in adults at 6 Months after COVID-19 infection
How many people get ‘long COVID’ – and who is most at risk?
Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline
Patients, clinicians seek answers to the mystery of ‘Long COVID’
Long Covid: 6-month consequences of COVID-19 in patients discharged from hospital
NICE Guideline: Managing the long-term effects of COVID-19
Commentary on Twitter
Nuestro estudio sobre Covid ?Persistente o de Largo recorrido se ha publicado finalmente en @SciReports
?https://t.co/ATFO5QO3kF pic.twitter.com/qwBikXyqll— Sonia Villapol (@svillapol) August 10, 2021
[Preprint] Phase 1/2 RCT: A booster dose is immunogenic and will be needed for older adults who have completed two doses vaccination with CoronaVac.
10 Aug, 2021 | 09:58h | UTC
Commentary on Twitter
6-month follow-up of people aged 60+ in early trials of Sinovac's CoronaVac in China. Authors conclude antibodies dropped too far, but a booster dose improved signs of immunity https://t.co/ooQ5M9gJZC (Preprint)
— Hilda Bastian, PhD (@hildabast) August 9, 2021
RCT: Safety and immunogenicity of heterologous vs. homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine.
9 Aug, 2021 | 00:06h | UTCInvited commentary: Optimising SARS-CoV-2 vaccination schedules – The Lancet
Related: Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination (several articles on the subject)
Commentary on Twitter
Just published @TheLancet
A randomized mix and match trial of AZ and Pfizer vaccination in >800 people shows that mixing is safe and can engender at least as good, if not better, immune response https://t.co/V40Dy59Ia8 by @XinxueLiu and colleagues pic.twitter.com/tKl59LFz4i— Eric Topol (@EricTopol) August 6, 2021
Bullous autoimmune dermatoses: clinical features, diagnostic evaluation, and treatment options.
10 Aug, 2021 | 08:44h | UTCBullous Autoimmune Dermatoses – Deutsches Ärzteblatt International
CDC study showed a reduced risk of reinfection with SARS-CoV-2 after covid-19 vaccination.
9 Aug, 2021 | 00:03h | UTC
Commentaries on Twitter
This is non randomized. The two biases are:
1. Behavior among those who got vaccinated likely different than those who don't
2. Likely those who didn't tested more aggressively
I would not cite this as many are doinghttps://t.co/rSkBC37uq0
— Vinay Prasad, MD MPH ?️? (@VPrasadMDMPH) August 7, 2021
Study shows that full #COVIDVaccination ⬇️ likelihood of being re-infected with #COVID19 compared to those who were previously had COVID but were not vaccinated (risk ⬆️ 2.3 fold)#GetVaccinated even if you have had COVID previouslyhttps://t.co/3dF3XPxwYp@fascinatorfun pic.twitter.com/ip6zTvNN86
— Kamlesh Khunti (@kamleshkhunti) August 7, 2021
COVID vaccine boosters: the most important questions.
8 Aug, 2021 | 23:52h | UTCCOVID vaccine boosters: the most important questions – Nature
Commentary on Twitter
I agree with @nataliexdean: “We just don’t have clear evidence of enough of a loss of efficacy to change our focus or distract from the main goal, which is trying to get as many people first doses” as possible." https://t.co/FEKB4vg0Dz
— Sanghyuk Shin (@sanghyuk_shin) August 6, 2021
More data showing one dose of Pfizer vaccine may be enough for individuals who’ve had COVID.
8 Aug, 2021 | 23:50h | UTCCommentary: One Dose of Pfizer Vaccine May Be Enough for Folks Who’ve Had COVID – HealthDay
Related:
Perspective | Is one vaccine dose enough if you’ve had COVID? What the science says.
Another study shows a single dose of mRNA vaccine may be enough for patients with previous Covid-19
Spain to give just one vaccine dose to under 55-year olds who had COVID-19
Perspective: Is one vaccine dose enough after COVID-19 infection?
France’s health authority recommends single vaccine shot for people who have had COVID-19
Covid-19: People who have had infection might only need one dose of mRNA vaccine
Commentary on Twitter
SARS-CoV-2 Antibody Responses After 1 and 2 Doses of the BNT162b2 Vaccine https://t.co/ARMdH8Yboo via @JAMANetworkOpen part of @JAMANetwork Small study but one that confirms the policy of many European countries in which one dose of vaccine is sufficient after having COVID.
— Carlos del Rio (@CarlosdelRio7) August 7, 2021
Case report: Systemic capillary leak syndrome after ChAdOx1 nCOV-19 (Oxford–AstraZeneca) vaccination.
8 Aug, 2021 | 23:49h | UTC
Antibody-mediated autoimmune encephalitis: A practical approach.
8 Aug, 2021 | 23:29h | UTC
SARS-CoV-2 Variants in Patients with Immunosuppression.
5 Aug, 2021 | 09:02h | UTCSARS-CoV-2 Variants in Patients with Immunosuppression – New England Journal of Medicine
Commentary on Twitter
In the pandemic, immunocompromised people (~3% of Americans) are not getting adequate recognition for the potential of in-host evolution of the virus (highlighted studies) and the need for far better approaches to protect them https://t.co/XDT1VxC9ZK @NEJM pic.twitter.com/ciw1WD9EzC
— Eric Topol (@EricTopol) August 4, 2021
RCT: Subcutaneous REGEN-COV antibody combination prevented symptomatic Covid-19 infection in previously uninfected household contacts of infected persons.
5 Aug, 2021 | 09:01h | UTCSubcutaneous REGEN-COV Antibody Combination to Prevent Covid-19 – New England Journal of Medicine
Related:
Commentary on Twitter
Subcutaneous REGEN-COV prevented symptomatic #COVID19 and asymptomatic #SARSCoV2 infection in previously uninfected household contacts. https://t.co/rRNFTjS9hX pic.twitter.com/B7qXeyWKUb
— NEJM (@NEJM) August 4, 2021
Cohort study: Six month follow-up of Multisystem Inflammatory Syndrome in Children.
3 Aug, 2021 | 09:05h | UTCSix Month Follow-up of Patients With Multisystem Inflammatory Syndrome in Children – Pediatrics (PDF)
A blood marker predicts who gets ‘breakthrough’ COVID (neutralizing antibodies).
3 Aug, 2021 | 09:01h | UTCA blood marker predicts who gets ‘breakthrough’ COVID – Nature
Related:
Covid-19 breakthrough infections in vaccinated health care workers.
Opinion | Should pregnant women have a COVID vaccine? The evidence says it’s safe and effective.
2 Aug, 2021 | 00:28h | UTC
ACOG and SMFM Recommend COVID-19 Vaccination for Pregnant Individuals – “ACOG encourages its members to enthusiastically recommend vaccination to their patients.”
2 Aug, 2021 | 00:31h | UTCAdditional reading:
Practice Advisory: COVID-19 Vaccination Considerations for Obstetric-Gynecologic Care
COVID-19 Vaccines and Pregnancy: Conversation Guide for Clinicians
Commentaries:
Obstetrician groups recommend COVID vaccine during pregnancy – Associated Press
Statements By Obstetrics Societies Strongly Advise Covid-19 Vaccinations For Pregnant Women – Forbes
Commentary on Twitter
Pregnant? ACOG and @MySMFM now recommend #COVID19 vaccination of pregnant individuals and urge our members to recommend that pregnant patients #GetVaccinated. The #covidvaccine is the best tool we have to save lives and end the pandemic: https://t.co/pUbLqqkKym #VaccinesWork pic.twitter.com/Ef2MOPv27L
— ACOG (@acog) July 30, 2021
NICE COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis.
30 Jul, 2021 | 12:14h | UTCNews release: NICE publishes new rapid guideline to diagnose and treat rare blood clotting condition associated with COVID-19 vaccination – National Institute for Health and Care Excellence
Related: Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (several articles and resources on the subject)
Evidence Analysis: Is piperacillin-tazobactam safe in patients with penicillin allergy?
29 Jul, 2021 | 11:05h | UTCIs piperacillin-tazobactam safe in patients with penicillin allergy? – PulmCrit
Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees.
28 Jul, 2021 | 10:19h | UTCRelated:
Case report: Thrombosis with Thrombocytopenia After the Messenger RNA–1273 Vaccine.
Laboratory testing for suspected COVID-19 vaccine–induced (immune) thrombotic thrombocytopenia.
Case series: Adjunct immune globulin for vaccine-induced thrombotic thrombocytopenia.
Case report: Successful treatment of vaccine-induced prothrombotic immune thrombocytopenia (VIPIT).
Vaccine-induced Immune Thrombotic Thrombocytopenia: Frequently Asked Questions
Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination
Case Report: Thrombotic Thrombocytopenia after Johnson & Johnson Vaccine
Papers Confirm Rare Thrombocytopenia Link to AstraZeneca Vaccine
Guidance on syndrome of Thrombosis and Thrombocytopenia occurring after coronavirus Vaccination
Commentary on Twitter
Vaccine-induced thrombotic thrombocytopenia (VITT or TTS) events are extremely rare w/ the adenovirus vector vaccines. A new report by @AstraZeneca @TheLancet addresses after 2nd AZ dose w/ details in 13 peoplehttps://t.co/Rf3euuQai5
1st dose : 8.1/ million
2nd dose: 2.3/million pic.twitter.com/GoOqWIRZfw— Eric Topol (@EricTopol) July 27, 2021